Geoffrey Oxnard, MD, associate professor of medicine at Harvard Medical School, discusses the advancements in treatments for lung cancer over the past 10 to 15 years. Even though targeted therapies and immunotherapies are not effective in a large percentage of patients with advanced non-small cell lung cancer (NSCLC), Dr. Oxnard believes genetic tumor testing should be carried out as early as possible based on the data that show when a patient is a candidate and responsive to these treatments, the benefits can be dramatic and long-lasting.

View the video by clicking here